HBM Healthcare Investments
HBM Healthcare Investments is a publicly listed investment company with a globally diversified portfolio of private and publicly traded companies in the healthcare sector. The firm focuses on promising companies in human medicine, biotechnology, medical technology, and diagnostics, supporting them strategically to enhance their growth and market presence. HBM Healthcare Investments is listed on the SIX Swiss Exchange under the symbol HBMN.
HBM Healthcare Investments
Bundesplatz 1, 6300 Zug, Schweiz
Portfolio
Neurelis licenses, develops, and commercializes product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry.
#Central Nervous System (CNS)
Swixx Biopharma expects a revenue jump to over EUR 700 million for the fiscal year 2022, resulting in a dividend income of CHF 10 million for HBM Healthcare Investments.
#Pharmaceutical Distribution
Fangzhou plans an IPO on the Hong Kong Stock Exchange, with a prospectus filed in November.
#Healthcare Platform
Viela Bio is a biotechnology company focused on treatments for severe inflammation and autoimmune diseases. HBM Healthcare Investments led a USD 75 million private placement with a USD 20 million investment.
#Biotechnology
1000Farmacie is the leading Italian e-pharmacy and digital healthcare platform with a vision to improve healthcare services and medicine delivery to customers and patients.
#Healthcare IT
Aculys Pharma is focused on the development and commercialization of innovations in neurology and psychiatry, with Series A financing supporting the clinical development of Pitolisant in Japan.
#Neurology and Psychiatry
ADARx is developing proprietary RNA platform and novel oligonucleotide delivery technologies for genetic, cardiometabolic, and CNS diseases.
#siRNA
Adrenomed is focused on rescuing vascular integrity to save lives of critically ill patients, with its lead product candidate Adrecizumab targeting sepsis and septic shock.
#Sepsis treatment
Alumis is developing ESK-001, a TYK2 inhibitor for plaque psoriasis, and A-005 for neuroinflammatory diseases, with plans for Phase 3 trials.
#Immunology & Inflammation
ALX Oncology is developing therapies that block the CD47 checkpoint pathway to help patients fight cancer.
#Oncology
Ambrx develops protein therapeutics using an expanded genetic code for site-specific conjugation, optimizing proteins for safety and efficacy.
#Oncology
Antiva is developing novel topical therapies to treat pre-cancerous lesions caused by HPV.
#Women’s health
Arrakis is pioneering RNA-targeted small molecules to treat disease by modifying RNA's biological function.
#Oncology
ArriVent is developing furmonertinib for exon-20 mutant NSCLC in a global Phase 3 trial.
#Oncology